About our e-newsletters
- Free e-newsletters
- Mayo Clinic expertise
- We do not share your e-mail address
Housecall, our weekly general-interest e-newsletter, keeps you up to date on a wide variety of health topics with timely, reliable, practical information, recipes, blogs, questions and answers with Mayo Clinic experts and more. Our biweekly topic-specific e-newsletters also include blogs, questions and answers with Mayo Clinic experts, and other useful information that will help you manage your health.
Housecall Archives
Mayo Clinic Housecall
Stay up to date on the latest health information.
What you get
- Free weekly e-newsletter
- Mayo Clinic expertise
- Recipes, tools and other helpful information
- We do not share your e-mail address
Drotrecogin Alfa (Intravenous Route)
Drug Information provided by: MicromedexUS Brand Names
|
Description
Drotrecogin alfa injection is used to treat severe cases of sepsis, a life threatening infection in the blood. This medicine has been shown to reduce the risk of death in patients with severe sepsis who are at high risk of death. This medicine works by decreasing inflammation and the formation of blood clots in blood vessels.
This medicine was available only with your doctor's prescription.
Drotrecogin alfa (Xigris®) injections were withdrawn from the U.S. market by Eli Lilly and Company on October 25, 2011.
Find Mayo Clinic on